Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine;Análise de custos do tratamento de episódios de descompensação aguda de insuficiência cardíaca. Levosimendan versus dobutamina

Arquivos Brasileiros de Cardiologia

Volumn 85, Issue 1, 2005, Pages 9-14

  Oliveira Jr , Mucio Tavares ^a   Follador, Wilson ^a   Martins, Maria Lucia Orlandi ^a   Canaviera, Roberta ^a   Tsuji, Rosana Lima Garcia ^a   Scipioni, Airton ^a   Barretto, Antonio Carlos Pereira ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Decompensated heart failure; Dobutamine; Inotropics; Levosimendan; Pharmacoeconomics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG COST; FEMALE; HEALTH CARE COST; HEART FAILURE; HEART FUNCTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MALE; MEDICAL FEE;

EID: 22644442630     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0066-782x2005001400003     Document Type: Article

References (28)

1. McMurray JJV, Stewart S. The burden of heart failure. Eur Heart J 2003; 5(suppl 1): 13-113.
2. Pereira-Barretto AC, Ramires JAF. Insuficiência Cardíaca-Um problemade Saúde Pública. Rev Bras Cardiol 2000; 2: 142-7.
3. Albanesi Filho FM. Epidemiologia da insuficiência Cardíaca. In: Pereira Barretto AC, Bocchi EA. Insuficiência Cardíaca. São Paulo: Editora Segmento, 2003:13-22.
4. DATASUS, www.datasus.gov.br
5. Revisão das II Diretrizes da Sociedade Brasileira de Cardiologia para o diagnóstico e tratamento da Insuficiência Cardíaca. Arq Bras Cardiol 2002; 79(suppl IV): 1-29.
6. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic hear failure. European Society of Cardiology. Eur Heart J 2001; 22: 1527-60.
7. Jain P, Massie BM, Gattis WA, Klein L, Gheorghiade M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J 2003; 145(suppl S): S3-S17.
8. O'Connor CM, Gattis WA, Uretisky BF et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999; 138: 78-86.
9. Ewy GA. Inotropic infusions for chronic congestive heart failure. J Am Coll Cardiol 1999; 33: 572-5.
10. Loh E. Overview: Old and new controversies in the treatment of advanced congestive heart failure. J Cardiac Fail 2001; 7: 1-7.
11. Greenberg B, Borghi C, Perrone S. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitizer, levosimendan?. Eur J Heart Faiul 2003; 5: 13-21.
12. Follath F, Cleland JGF, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (The LIDO study): a randomized double-blind trial. Lancet 2002; 360: 196-202.
13. Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and Beta-blockers: Is there a need for new guidelines? J Card Fail 2001; 7(suppl 1): 8-12.
14. Feinglass J, Martin GJ, Lin E, Johnson MR, Gheorghiade M. Is heart failure survival improving? Evidence from 2323 elderly patients hospitalized between 1989-2000. Am Heart J 2003; 146: 111-14.
15. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
16. The CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9-13.
17. MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-07.
18. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.
19. The digitalis investigation group - DIG. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
20. The RALES study. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
21. Michalsen A, König G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998; 80: 437-441.
22. Luzier AB, Forrest A, Feuerstein SG et al. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol 2000; 86: 519-23.
23. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11942 elderly patients with heart failure. Am J Med 2002; 113: 650-56.
24. Cleland JGF, Ghosh J, Fremantle N et al. Clinical trials update and cumulative meta-analyses from the American College of cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS, and cardiac resynchronization therapy in heart failure. Eur J Heart Fail 2004; 6: 501-08.
25. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs 2001; 61: 613-27.
26. Moiseyev VS, Poder P, Andrejevs N et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-32.
27. Follath F for the Steering Committee and Investigators. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J 2003; 4 (suppl 2): 34S-38S.
28. Cleland JGF, Takala A, Apajasalo M et al. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003; 5: 101-08.